The EMBRACE Study: Enflonsia Monoclonal in Babies - RSV Antibody Concentration Evaluation

ClinicalTrials.gov ID: NCT07824167

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07824167. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Longitudinal Serum and Mucosal RSV Antibodies Following Clesrovimab (Enflonsia™, Merck) Administration in Infants During Their First Respiratory Season or [The EMBRACE Study: Enflonsia™ Monoclonal in Babies - RSV Antibody Concentration Evaluation]

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Clesrovimab is an FDA-approved antibody drug recommended for infants younger than 8 months who are entering their first respiratory syncytial virus (RSV) season and whose mothers did not receive an RSV vaccine during pregnancy. It is given to help prevent severe RSV illness. This study will measure clesrovimab and other RSV antibodies in infants' blood and noses to learn how much of the drug reaches the nose, how long the antibodies remain, and how antibody levels change if an infant becomes infected with RSV.

Study identification

NCT ID: NCT07824167
Recruitment status: Not yet recruiting
Study type: Interventional
Phase: Phase 4
Lead sponsor: Emory University; Other
Enrollment: 24 participants

Conditions and interventions

Conditions

RSV Infection

Interventions

Clesrovimab Biological

Biological

Eligibility (public fields only)

Age range: Up to 8 Months
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 2026 (Estimated)
Primary completion: Mar 2028 (Estimated)
Completion: Mar 2028 (Estimated)
Last update posted: Nov 12, 2026

2026 – 2028

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Emory Children's Center-Vaccine Research Clinic	Atlanta	Georgia	30322	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07824167, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 12, 2026 · Synced Nov 15, 2026